The Biotech Startups Podcast

The Delivery Problem Behind Moderna's Breakthrough | Örn Almarsson (3/4)

Sep 21, 2026
Örn Almarsson, a biotech executive and drug-delivery scientist, recounts his path through Johnson & Johnson, Alkermes, and Moderna. He discusses acquisition-driven pharma, transforming Alkermes, layoffs, patent cliffs, and biotech’s volatile cycles. Then he reveals the engineering challenge of therapeutic mRNA delivery, from evading immune alarms to scaling production from micrograms to kilograms.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Why Pharma Chooses Acquisitions Over Discovery

  • J&J favored acquiring de-risked medicines, while Merck emphasized internal discovery and biotechs necessarily absorb early scientific risk.
  • J&J’s commercialization strength let it acquire assets from innovators such as MIT professor Michael Cima’s bladder-cancer device company.
ANECDOTE

A Merck Network Opened Alkermes’ Next Chapter

  • Örn Almarsson joined Alkermes after a Merck connection introduced him to Elliot Ehrich.
  • The company shifted from engineering-heavy work toward balanced chemistry and organic product development.
ANECDOTE

Alkermes Rebuilt After A $30 Million Shock

  • A Lilly program’s cancellation erased nearly $30 million in annual revenue shortly after Örn Almarsson joined Alkermes.
  • After layoffs and a bootstrap period, the company rebuilt around future capabilities and eventually developed ARISTADA.
Get the Snipd Podcast app to discover more snips from this episode
Get the app